Als u de informatie op kanker-actueel waardeert wilt u ons misschien steunen met een donatie op
RABO 37.29.31.138 t.n.v. Stichting Gezondheid Actueel in Terneuzen.
Onze IBANcode is NL79 RABO 0372 9311 38
BIC/SWIFTCODE RABONNL2U
Wij zijn een ANBI organisatie, dus uw donatie is in principe aftrekbaar voor de inkomstenbelasting. Ook kunt u als donateur voordeel krijgen bij verschillende bedrijven. Bv ook op AHCC supplementen.
Alle abstracten gepresenteerd tijdens de SGO 2019 (50th Annual Meeting of the Society of Gynecologic Oncology) staan in deze PDF. waaronder ook onderstaande studie.
27 maart 2019: Bron: SGO 2019
Wanneer vrouwen met een positief uitstrijkje dat aantoont dat zij draagster zijn van het HPV virus (humaan papillomavirus) dagelijks gedurende 6 maanden een AHCC extract nemen dan verdwijnt binnen 6 maanden de HPV infectie bij 63,4 procent van de draagsters tegenover bij 10,5 procent van de vrouwen die een placebo kregen. Dit blijkt uit een gerandomiseerde placebo gecontroleerde studie bij totaal 50 vrouwen met een aantoonbare HPV infectie.
Dr. Smith en haar collega's wilden onderzoeken wat de effecten zouden zijn op het dagelijks gebruik van een AHCC supplement (3 gram) oraal in te nemen. Om op die manier HPV-infecties te bestrijden bij vrouwen van wie hun PAP-uitstrijkjes positief waren en de aanwezigheid van het HPV virus hadden aangetoond. (Het HPV virus is heel vaak oorzaak van Baarmoederhalskanker en ook blijkt meer en meer dat het HPV virus vaak ook de oorzaak van Mond- en Keelkanker is)
De onderzoekers wilden ook de duurzaamheid van de reactie op het supplement observeren om eventuele nadelige gevolgen in vergelijking met een placebo vast te stellen.
Totaal 50 patiënten (met positief uitstrijkje) werden gerandomiseerd ingedeeld in twee groepen (25 vs 25), om ofwel AHCC 3000 mg (genomen als zes 500-mg-capsules) eenmaal daags oraal op een lege maag gedurende 6 maanden in te nemen, gevolgd door een placebo (zes capsules) eenmaal daags oraal op een lege maag. Of om een placebo te ontvangen: (zes capsules) oraal eenmaal daags op een lege maag gedurende 6 tot 12 maanden.
Een voorlopige analsye bevestigt dat bij 63,4 procent van de deelnemende vrouwen die het AHCC supplement hadden gekregen het HPV virus was verdwenen. Bij slechts 2 vrouwen (10,5 procent) uit de placebogroep was het HPV virus verdwenen op 1-jaars meting.
Dr. Smith zegt, “Supplementation with active hexose-correlated compound was well tolerated, with minimal potential for drug/supplement interactions.” Dus AHCC is een effectief en duurzaam voedingssupplement zonder extra bijwerkingen. (Een AHCC extract zou dus wellicht een goed alternatief voor vaccinatie kunnen zijn?)
Dr Smith zegt ook nog tijdens de presentatie het volgende:
“These phase II results are a major milestone in our research. We now plan to optimize and individualize treatment. The duration of supplementation with the compound after the first negative result also needs further evaluation.”
“Our hope is that, ultimately, the supplement will be used to eradicate HPV in both women and men.”
Het volledige studierapport: https://www.frontiersin.org/articles/10.3389/fonc.2019.00173/full is gratis in te zien.
Hier het abstract van de studie:
Pre-clinical in vitro and in vivo studies demonstrated durable clearance of HR-HPV infections. The preliminary data from the two pilot studies suggested that AHCC supplementation supports the host immune system for successful clearance of HR-HPV infections. A confirmatory phase II randomized, double-blinded, placebo-controlled study is ongoing.
From Bench to Bedside: Evaluation of AHCC Supplementation to Modulate the Host Immunity to Clear High-Risk Human Papillomavirus Infections
Judith A. Smith1,2*, 
Lata Mathew1, 
Anjali Gaikwad1, Barbara Rech3, Maryam N. Burney1, Jonathan P. Faro4, Joseph A. Lucci III1,2, Yu Bai5, Randall J. Olsen6 and 
Teresa T. Byrd1- 1Department of Obstetrics, Gynecology and Reproductive Sciences, UTHealth McGovern Medical School, Houston, TX, United States
- 2Department of Pharmacy, Memorial Hermann Cancer Center, Houston, TX, United States
- 3UT Physicians Women's Center, Houston, TX, United States
- 4Specialists in Obstetrics & Gynecology, Houston, TX, United States
- 5Department of Pathology, UTHealth McGovern Medical School, Houston, TX, United States
- 6Department of Molecular Pathology, Institute for Academic Medicine, Houston Methodist Research Institute, Houston, TX, United States
Objective: There is currently no effective medicine or supplement for clearance of high risk- human papillomavirus (HR-HPV) infections. We have taken a systematic approach evaluating the potential use of AHCC supplementation to support clearance of HR-HPV infections. The primary objective of this research was to evaluate AHCC supplementation to modulation of the host immune system to clear HR-HPV infections from bench to bedside.
Methods: Cervical cancer cells, CaSki (HPV16+), HeLa(HPV18+), SiHa(HPV16/18+), and C-33A(HPV−), were treated in vitro with AHCC 0.42 mg/mL daily x7 days then observed x7 days with daily sample collection. A confirmatory study in cervical cancer mouse models, SiHa(HPV16/18+) and C-33A(HPV−), was conducted: mice were divided into three groups per cell line then dosed with AHCC 50 mg/kg/d (N = 10), or vehicle alone (N = 10), or no supplementation (N = 10) for a total of 90 days followed by 30 days of observation. Tumors were measured 3x/week and blood samples collected bi-weekly to evaluate interferon (IFN) alpha(α), beta(β), and gamma(γ) and immunoglobulin G(IgG) by immunoassays. Tumors were evaluated for HR-HPV expression by PCR. Two pilot studies of 10 patients each were conducted in women with confirmed persistent HR-HPV+ infections. The 1st study evaluated AHCC 3g from 5 weeks up to 6 months and 2nd study evaluated AHCC 1g < 8 months. HR-HPV DNA status and the immune panel were monitored at each visit.
Results: HR-HPV clearance was observed in vitro and confirmed in the animal studies as a durable response. Four of six (66.7%) patients had confirmed HR-HPV clearance after 3–6 months of AHCC 3g. Similarly, 4 of 9 (44%) patients had confirmed HR-HPV clearance after 7 months of AHCC 1g. Suppression of IFNβ <25 pg/mL was observed in those clearing the HR-HPV infection.
Conclusion: Pre-clinical in vitro and in vivo studies demonstrated durable clearance of HR-HPV infections. The preliminary data from the two pilot studies suggested that AHCC supplementation supports the host immune system for successful clearance of HR-HPV infections. A confirmatory phase II randomized, double-blinded, placebo-controlled study is ongoing.
Author Contributions
JS contributed to conceptualization, data curation, formal analysis, funding acquisition, investigation, methodology, project administration, supervision, writing—original draft and editing. LM and AG contributed to data curation, investigation, formal analysis, methodology, validation, writing—original draft, review and editing. BR and MB contributed to data curation, investigation, writing—review and editing. JF contributed to methodology, investigation, writing—review and editing. JL and TB contributed to investigation, writing—review and editing. YB and RO contributed to methodology, supervision, writing—review and editing.
Funding
This research was partially supported by an unrestricted research grant from Amino Up Chemical Company; Larry C. Gilstrap M.D. Center for Perinatal and Women's Health Research; and WHIM Research Program philanthropic funds; NIH 1R03CA212935.
Conflict of Interest Statement
JS has been principal investigator on unrestricted research grants from Amino Up Chemical Company to the institution for preliminary preclinical studies.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1. American Cancer Society. Global Burden of Cancer in Women: Current Status, Trends, and Interventions. Available online at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-burden-of-cancer-in-women.pdf (Accessed July 9, 2018).
2. Lombard I, Vincent-Salomon A, Zafrani B, de la Rochefordiere A, Clough K, Favre M, et al. Human papillomavirus genotype as a major determinant of the course of cervical cancer. J Clin Oncol. (1998) 16:2613–9. doi: 10.1200/JCO.1998.16.8.2613
3. Harris RWC, Brinton LA, Cowdell RH, Skegg DC, Smith PG, Vessey MP, et al. Characteristics of women with dysplasia or carcinoma in situ of the cervix uteri. Br J Cancer. (1980) 42:359–69. doi: 10.1038/bjc.1980.246
4. Furumoto H, Irahara M. Human papillomavirus (HPV) and cervical cancer. J Med Invest. (2002) 49:124–33.
5. Munoz N, Bosch FX, de Sanjose S, Herreor R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. (2003) 348:518–27. doi: 10.1056/NEJMoa021641
6. Andrei G, Snoeck R, Piette J, Delvenne P, DeClercq E. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines. Oncol Res. (1998) 10:523–31.
7. Andrei G, Snoeck R, Schols D, De Clercq E. Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. (2000) 12:397–408. doi: 10.3727/096504001108747855
8. Schiffman M, Wheeler CM, Castle PE. Human papillomavirus DNA remains detectable longer than related cervical cytologic abnormalities. J Infect Dis. (2002) 186:1169–72. doi: 10.1086/343816
9. Uno K, Kosuna K, Sun B, Fujii H, Wakame K, Chikumaru S, et al. Active Hexose Correlated Compound (AHCC) improves immunological parameters and performance status of patients with solid tumors. Biotherapy. (2000) 14:303–9.
10. Gao Y, Zhang D, Sun B, Fujii H, Kosuna K, Yin Z. Active hexose correlated compound enhances tumor surveillance through regulating both innate and adaptive immune responses. Cancer Immunol Immunother. (2006) 55:1258–66. doi: 10.1007/s00262-005-0111-9
11. Hirose A, Sato E, Fujii H, Sun B, Nishioka H, Aruoma OI. The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice. Toxicol Appl Pharmacol. (2007) 222:152–8. doi: 10.1016/j.taap.2007.03.031
12. Hunter RJ, Fujii H, Wakame K, Gaikwad A, Wolf JK, Smith JA. Evaluation of active hexose correlated compound (AHCC) in combination with PEGylated liposomal doxorubicin for treatment of ovarian cancer. Int J Appl Res Nat Prod. (2011) 4:6–11. Available online at: http://www.doaj.org/doaj?func=openurl&issn=19406223&genre=journal
13. Matsui Y, Uhara J, Satoi S, Kaibori M, Yamada H, Kitade H, et al. Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study. J Hepatol. (2002) 37:78–86. doi: 10.1016/S0168-8278(02)00091-0
14. Kawaguchi Y. Improved survival of patients with gastric cancer or colon cancer when treated with active hexose correlated compound (AHCC): effect of AHCC on digestive cancer. Nat Med J. (2009) 1:1–6.
15. Doorbar J. Host control of human papillomavirus infection and disease. Best Prac Res Clin Obstet Gynaecol. (2018) 47:27–41 doi: 10.1016/j.bpobgyn.2017.08.001
16. Wilson EB, Yamada DH, Elsaesser H, Herskovitz J, Deng J, Cheng G, et al. Blockage of chronic type I interferon signaling to control persistent LCMV infection. Science. (2013) 340:202–7. doi: 10.1126/science.1235208
17. Teijaro JR, Ng C, Lee AM, Sullivan BM, Sheehan KC, Welch M, et al. Persistent LCMC infection is controlled by blockade of type I interferon signaling. Science. (2013) 340:207–11. doi: 10.1126/science.1235214
18. Fujita T, Kimura Y, Miyamoto M, Barsoumain EI, Taniguchi T. Induction of endogenous IFN- alpha and IFN-beta genes by a regulatory transcription factor, IRF-1. Nature. (1989) 337:270–2. doi: 10.1038/337270a0
19. Honda K, Tanguchi T. Toll-like receptor signaling and IRF transcription factors. IUBMB Life. (2006) 58:290–5. doi: 10.1080/15216540600702206
20. Lace MJ, Anson JR, Haugen TH, Turek LP. Interferon regulatory factor (IRF)-2 activates the HPV-16 E6-E7 promoter in keratinocytes. Virology. (2010) 399:270–9. doi: 10.1016/j.virol.2009.12.025
21. Kimura T, Nakayama K, Penninger J, Kitagawa M, Harada H, Matsuyama T, et al. Involvement of the IRF-1 transcription factor in antiviral responses to interferons. Science. (1994) 264:1921–4. doi: 10.1126/science.8009222
22. Kano A, Haruyama T, Akaike T, Watanabe Y. IRF-1 is an essential mediator in IFN-gamma-induced cell cycle arrest and apoptosis of primary hepatocytes. Biochem Biophys Res Commun. (1999) 257:672–7. doi: 10.1006/bbrc.1999.0276
23. Lace MJ, Anson JR, Klingelhutz AJ, Harada H, Taniguchi T, Bossler AD, et al. Interferon-beta treatment increases human papillomavirus early gene transcription and viral plasmid genome replication by activating regulatory factor (IRF)-1. Carcinogenesis. (2009) 30:1336–44. doi: 10.1093/carcin/bgp150
Gerelateerde artikelen
- Paddenstoelenextract - AHCC geneest bij 60 procent (versus 10 procent bij placebo) binnen 6 maanden HPV positieve patienten
- Wetenschappelijk commentaar op studie AHCC bij leverkanker.
- Het effect van functionele voeding AHCC - mix van medicinale paddestoelen - bij levertumoren positief en significant bewijst negenjarige studie.
- AHCC, een mix van paddestoelen zorgt voor groot therapeutisch effect bij levertumoren blijkt uit fase III studie
Plaats een reactie ...
Reageer op "Paddenstoelenextract - AHCC geneest bij 60 procent (versus 10 procent bij placebo) binnen 6 maanden HPV positieve patienten"